Raymond James Financial Inc. Grows Stock Holdings in CRISPR Therapeutics AG $CRSP

Raymond James Financial Inc. lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 86,666 shares of the company's stock after buying an additional 4,571 shares during the period. Raymond James Financial Inc. owned about 0.10% of CRISPR Therapeutics worth $2,949,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in shares of CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock worth $345,929,000 after buying an additional 1,192,336 shares in the last quarter. Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after purchasing an additional 33,711 shares during the period. Bank of America Corp DE lifted its position in CRISPR Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 1,211,509 shares of the company's stock valued at $47,685,000 after purchasing an additional 129,746 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in CRISPR Therapeutics by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company's stock valued at $27,166,000 after purchasing an additional 13,865 shares during the period. Finally, Two Sigma Investments LP lifted its position in CRISPR Therapeutics by 71.1% during the fourth quarter. Two Sigma Investments LP now owns 306,272 shares of the company's stock valued at $12,055,000 after purchasing an additional 127,219 shares during the period. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded up $3.96 on Thursday, hitting $55.77. 1,488,153 shares of the stock traded hands, compared to its average volume of 2,534,690. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of -10.27 and a beta of 1.81. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The firm has a 50 day simple moving average of $56.57 and a two-hundred day simple moving average of $45.57.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company's revenue was up 72.5% on a year-over-year basis. During the same period last year, the firm earned ($1.49) EPS. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of research analyst reports. Royal Bank Of Canada increased their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research report on Tuesday, August 5th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. HC Wainwright increased their price target on shares of CRISPR Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Thursday, August 7th. Needham & Company LLC reiterated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Finally, Barclays increased their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $71.60.

Insider Activity at CRISPR Therapeutics

In other news, Director Simeon George acquired 989,812 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the transaction, the director directly owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.